Patents by Inventor Graeme Fraser

Graeme Fraser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
    Patent number: 12458641
    Abstract: Disclosed is use of NK3R antagonists for the therapeutic treatment leptin-related disease.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: November 4, 2025
    Assignee: Ogeda SA
    Inventors: Hamid Hoveyda, Graeme Fraser
  • PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS
    Publication number: 20250002475
    Abstract: Compounds of formula (I), or the pharmaceutically acceptable salts and/or the solvates thereof, wherein m, n, R1, R2, R3, R4, R5, L, Ar1 and Ar2 are as defined as disclosed, which are useful as inhibitors of METTL3 (N6-adenosine-methlytransferase subunit) activity, in particular for the treatment of proliferative diseases such as cancers.
    Type: Application
    Filed: July 25, 2024
    Publication date: January 2, 2025
    Applicant: EPICS THERAPEUTICS
    Inventors: Guillaume DUTHEUIL, Graeme FRASER, Catherine SORLET, Killian OUKOLOFF, François LENOIR, Julien KORAC
  • Piperidine derivatives as METTL3 inhibitors
    Patent number: 12091400
    Abstract: Compounds of formula (I), or the pharmaceutically acceptable salts and/or the solvates thereof, wherein m, n, R1, R2, R3, R4, R5, L, Ar1 and Ar2 are as defined as disclosed, which are useful as inhibitors of METTL3 (N6-adenosine-methlytransferase subunit) activity, in particular for the treatment of proliferative diseases such as cancers.
    Type: Grant
    Filed: January 19, 2024
    Date of Patent: September 17, 2024
    Assignee: EPICS THERAPEUTICS
    Inventors: Guillaume Dutheuil, Graeme Fraser, Catherine Sorlet, Killian Oukoloff, François Lenoir, Julien Korac
  • PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS
    Publication number: 20240270716
    Abstract: Compounds of formula (I), or the pharmaceutically acceptable salts and/or the solvates thereof, wherein m, n, R1, R2, R3, R4, R5, L, Ar1 and Ar2 are as defined as disclosed, which are useful as inhibitors of METTL3 (N6-adenosine-methlytransferase subunit) activity, in particular for the treatment of proliferative diseases such as cancers.
    Type: Application
    Filed: January 19, 2024
    Publication date: August 15, 2024
    Applicant: EPICS THERAPEUTICS
    Inventors: Guillaume DUTHEUIL, Graeme FRASER, Catherine SORLET, Killian OUKOLOFF, François LENOIR, Julien KORAC
  • NOVEL N-ACYL-[3-SUBSTITUTED]-[8-SUBSTITUTED]-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
    Publication number: 20240199618
    Abstract: A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
    Type: Application
    Filed: August 21, 2023
    Publication date: June 20, 2024
    Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
  • N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
    Patent number: 11731974
    Abstract: A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: August 22, 2023
    Assignee: Ogeda SA
    Inventors: Hamid R. Hoveyda, Guillaume Dutheuil, Graeme Fraser
  • NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC OR COSMETIC TREATMENT OF EXCESS BODY FAT
    Publication number: 20230039022
    Abstract: Disclosed is use of NK3R antagonists for the therapeutic treatment leptin-related disease.
    Type: Application
    Filed: September 13, 2022
    Publication date: February 9, 2023
    Inventors: Hamid Hoveyda, Graeme Fraser
  • NK-3 receptor antagonists for therapeutic treatment of leptin-related disease
    Patent number: 11478472
    Abstract: Disclosed is use of NK3R antagonists for the therapeutic treatment leptin-related disease.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: October 25, 2022
    Assignee: Ogeda SA
    Inventors: Hamid Hoveyda, Graeme Fraser
  • NOVEL N-ACYL-[3-SUBSTITUTED]-[8-SUBSTITUTED]-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
    Publication number: 20210094959
    Abstract: A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
    Type: Application
    Filed: October 8, 2020
    Publication date: April 1, 2021
    Inventors: Hamid R. Hoveyda, Guillaume Dutheuil, Graeme Fraser
  • N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
    Patent number: 10836768
    Abstract: A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: November 17, 2020
    Assignee: Ogeda SA
    Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
  • NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC TREATMENT OF LEPTIN-RELATED DISEASE
    Publication number: 20200222399
    Abstract: Disclosed is use of NK3R antagonists for the therapeutic treatment leptin-related disease.
    Type: Application
    Filed: February 20, 2020
    Publication date: July 16, 2020
    Inventors: Hamid HOVEYDA, Graeme FRASER
  • NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
    Patent number: 10624890
    Abstract: Disclosed is use of NK3R antagonists for the therapeutic treatment of pathological excess body fat and/or prevention of body fat gain in patients. Also disclosed is a cosmetic method for stimulating the loss of excess of body fat, including the administration of a NK-3 receptor antagonist.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: April 21, 2020
    Assignee: OGEDA SA
    Inventors: Hamid Hoveyda, Graeme Fraser
  • Macrocyclic ghrelin receptor modulators and methods of using the same
    Patent number: 10258602
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: April 16, 2019
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
  • NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
    Publication number: 20190092777
    Abstract: A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
    Type: Application
    Filed: November 29, 2018
    Publication date: March 28, 2019
    Inventors: Hamid HOVEYDA, Guillaume DUTHEUIL, Graeme FRASER
  • N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
    Patent number: 10214533
    Abstract: Novel compounds of Formula I and their use in therapeutic treatments.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: February 26, 2019
    Assignee: OGEDA SA
    Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
  • N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
    Patent number: 10183948
    Abstract: A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: January 22, 2019
    Assignee: OGEDA SA
    Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
  • NK-3 RECEPTOR ANTAGONISTS FOR THERAPEUTIC OR COSMETIC TREATMENT OF EXCESS BODY FAT
    Publication number: 20180289705
    Abstract: Disclosed is use of NK3R antagonists for the therapeutic treatment of pathological excess body fat and/or prevention of body fat gain in patients. Also disclosed is a cosmetic method for stimulating the loss of excess of body fat, including the administration of a NK-3 receptor antagonist.
    Type: Application
    Filed: March 16, 2016
    Publication date: October 11, 2018
    Inventors: Hamid HOVEYDA, Graeme FRASER
  • NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
    Publication number: 20180237446
    Abstract: Novel compounds of Formula I and their use in therapeutic treatments.
    Type: Application
    Filed: April 18, 2018
    Publication date: August 23, 2018
    Inventors: Hamid HOVEYDA, Guillaume DUTHEUIL, Graeme FRASER
  • Macrocyclic Ghrelin Receptor Modulators and Methods of Using the Same
    Publication number: 20180228768
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 16, 2018
    Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
  • Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
    Patent number: 10030025
    Abstract: Novel compounds of Formula I and their use in therapeutic treatments.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: July 24, 2018
    Assignee: OGEDA SA
    Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser